<DOC>
	<DOCNO>NCT01186939</DOCNO>
	<brief_summary>At conclusion study AZA PH GL 2003 CL 001 ( NCT00071799 ) , eligible participant could enrol optional extension phase order continue treatment azacitidine become commercially available ; continue treatment ethical safety reason provide additional efficacy data .</brief_summary>
	<brief_title>An Extension Study AZA PH GL 2003 CL 001 Allowing Continuation Azacitidine Treatment Patients With Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description>At conclusion study AZA PH GL 2003 CL 001 ( NCT00071799 ) , eligible participant could enrol optional extension phase order continue treatment azacitidine become commercially available ; continue treatment ethical safety reason provide additional efficacy data . During extension phase , participant treat base 28-day cycle monitor hematologic , nonhematologic , renal toxicity . Recommended monitoring procedure include complete blood count differential platelet least cycle prior dose need , bone marrow biopsy aspirate clinically indicate , additional test frequent monitoring investigator 's discretion base patient 's clinical status . The azacitidine dose could modify toxicity . Laboratory data collect extension phase .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Participants consider eligible randomized azacitidine treatment primary study receive azacitidine time study closure , complete 12 month treatment observation primary study , sign informed consent document extension phase study . See study : AZA PH GL 2003 CL 001 list inclusion criterion primary study . None specific extension phase study See study : AZA PH GL 2003 CL 001 list exclusion criterion primary study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>MDS</keyword>
</DOC>